Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21739121 | 0.90 | TDP1 (0.36) | TDP1GFERALDH1A1 | |
| SCHEMBL22052762 | 0.90 | TDP1 (0.36) | TDP1GFERALDH1A1 | |
| SCHEMBL22052763 | 0.90 | TDP1 (0.36) | TDP1GFERALDH1A1 | |
| SCHEMBL24667087 | 0.90 | TDP1 (0.36) | TDP1GFERALDH1A1 | |
| SCHEMBL17406830 | 0.77 | CHRNB2 (0.38) | TDP1GFERALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL21740354 | 0.77 | CHRM2 (0.35) | TDP1ALDH1A1 | |
| SCHEMBL14490270 | 0.76 | TDP1 (0.39) | TDP1MEN1KMT2ABRD4BRD2 | |
| SCHEMBL27106792 | 0.75 | KMT2A (0.42) | TDP1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27106788 | 0.75 | KMT2A (0.42) | TDP1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9881641 | 0.75 | DPP4 (0.40) | TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNB1, KCNJ2, KCNB2 | TDP1 3459/4885GFER 4011/4885ALDH1A1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.